CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
ALT-711 (alagebrium chloride)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00277875
NCT00277875Phase 2Completed
CompareCT.gov

The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.

Synvista Therapeutics, Inc·interventional·Posted Jan 18, 2006·Updated Aug 27, 2009

In Brief

A Phase 2 clinical trial evaluating ALT-711 (alagebrium chloride) for Cardiovascular Disease. Completed, across 1 site.

Detailed Summary

Determine whether increasing arterial distensibility by decreasing advanced glycation end-product (AGE) cross-link components of vascular stiffness improves (a) endothelial-mediated vasoreactivity at rest, as assessed by flow-mediated vasodilation (FMD), and (b) endothelial-mediated vasoreactivity after exercise, as assessed by pulse perfusion-mediated vasodilation (PPMV).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 18, 2006
Enrollment StartFeb 1, 2004
Primary CompletionDec 1, 2004
Study CompletionJan 1, 2006
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 20.5 years ago

Interventions

ALT-711 (alagebrium chloride)drug